Over four months, I conducted 30+ in-depth interviews with C-suite executives across Fortune 500 companies in healthcare, retail, financial services, manufacturing, and professional services. The brief: understand how these organizations are actually approaching Generative AI adoption — not the press release version, the real version.
What I found was almost entirely counterintuitive. The barriers to adoption aren't technical. The leaders who are winning aren't the most tech-forward. And the companies that are failing are usually failing for the same preventable reason.
"Every executive I spoke to had a GenAI pilot. Almost none of them had a GenAI strategy."
The overwhelming majority of executives — regardless of industry or technical sophistication — cited the same primary barrier: trust. Not trust in the technology's capability. Trust in the outputs, trust in the process, trust in the people who are deploying it.
Specifically, three trust gaps kept surfacing:
The companies making real progress had systematically addressed all three. They had built validation workflows, governance frameworks, and clear use-case portfolios that gave executives and middle managers the confidence to move.
Here's something nobody talks about in the GenAI discourse: most adoption decisions are made by middle managers, not C-suite. The executives I spoke to understood this viscerally. Their job was setting direction and removing blockers. The actual yes-or-no decisions — whether a tool gets used, whether a workflow changes — happen two to three levels below them.
The organizations succeeding at adoption had invested heavily in middle management enablement: training, clear use cases, permission frameworks, and crucially, a way to surface success stories from the team level up. The organizations struggling had done great executive alignment work and almost no frontline enablement.
"Every executive I spoke to could name their GenAI strategy. Almost none could tell me whether their VP of Marketing had used it in the last week."
General-purpose GenAI tools — ChatGPT, Claude, Gemini — are universally known and widely tried. But the organizations extracting the most value aren't using general-purpose tools for general-purpose tasks. They're using either fine-tuned models or heavily prompted general models applied to specific, high-value workflows in their vertical.
In healthcare: clinical documentation, prior authorization drafting, patient communication templates. In financial services: regulatory document summarization, client communication personalization, risk narrative generation. In manufacturing: maintenance log analysis, supplier communication, technical specification translation.
The pattern: the narrower the use case and the higher the stakes, the higher the ROI.
The implications for firms selling into these organizations are significant. The conversation is no longer "can you help us with AI?" — it's "can you help us build the trust infrastructure, governance frameworks, and vertical-specific use case portfolios that turn our pilots into programs?"
That's a very different engagement than technology implementation. It's organizational change management with AI as the catalyst. The firms that understand this — and position accordingly — are going to win an outsized share of the market over the next 24 months.
The executives who are getting this right are not the most technically sophisticated. They're the ones who asked the human questions first: Who needs to trust what? Who makes the actual decisions? Where does this create enough value to change behavior? Answer those questions before you build the tech stack, and the adoption follows.
Building a GenAI strategy for your organization or clients?
Let’s Build a Roadmap →